Abstract library

21 results for "Grønbæk".
#2782 Clinical Efficacy of Peptide Receptor Radionuclide Therapy in Patients with Neuroendocrine Neoplasm
Introduction: Peptide receptor radionuclide therapy (PRRT) is an established treatment of metastatic neuroendocrine neoplasms (NEN) with positive effects on both progression free survival (PFS) and overall survival (OS). Only a few previous studies have investigated the effect of a second series and hence a retreatment with PRRT.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Medical Student Michala Danielle Zacho
#2783 Use of Plasma Proteins to Predict Progressive Disease in Patients with Small Intestinal Neuroendocrine Tumours
Introduction: Prediction of progression in small intestinal neuroendocrine tumors (SI-NET).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD PhD Roger Belusa
#209 A Randomized, Cross-Over Study in Patients with Neuroendocrine Tumors (NETs) to Assess Patient Preference of Lanreotide Autogel Given by Either Self/Partner or Healthcare Professional
Introduction: Ready-to-use Lanreotide Autogel provides the option of self/partner administration for patients with NET. This is anticipated to reduce treatment cost and negative impact on daily life.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MSc Anders Öhberg
#311 Treatment and Prognosis of Patients with Poorly Differentiated Neuroendocrine Tumors
Introduction: Poorly differentiated neuroendocrine tumors (PDEC) represent less than 10% of all neuroendocrine tumors but have a poor prognosis.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Henning Grønbæk
#365 FDOPA PET/CT has a Significant Clinical Impact on the Management of Patients with Neuroendocrine Tumors
Introduction: Studies suggest that positron emission tomography (PET) using the dopamine-synthesis tracer [18F]fluoro-dihydroxyphenylalanine (FDOPA) may improve the clinical management of patients with NET.
Conference:
Category: Basic
Presenting Author: Dr. Michael Sørensen
#487 Validation of Chromogranin A Assays in Patients with Neuroendocrine Tumors
Introduction: CgA is the most important biochemical marker for evaluation of NETs. Different assays with different accuracy exist.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Lise Brehm Høj
Keywords: neuroendocrine, CgA, assay
#776 Goblet Cell Carcinoids: Characteristics of a Danish Cohort of 85 Patients
Introduction: Appendiceal Goblet cell carcinoids (GCC) exhibit neuroendocrine and adenocarcinoma features.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Pathology, grading, staging
Presenting Author: MD Ingrid H. Olsen
Keywords: prognosis
#783 A Comparison of Three Chromogranin A Assays in Patients with Neuroendocrine Tumors
Introduction: Chromogranin A (CgA) is the most important general tumor marker used in the diagnosis and follow-up of patients with neuroendocrine tumors (NET). CgA assays may have different sensitivities, which is of importance for the clinical diagnosis and handling of NET patients.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Biomarkers
Presenting Author: Dr. Henning Grønbæk
#784 Incidence and Survival of Patients with Small Intestinal Neuroendocrine Tumors in a Danish NET Center
Introduction: Small intestinal neuroendocrine tumors (NET) have increased in incidence during the past decades. However, time trends from the Nordic countries are sparse.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr. Henning Grønbæk
Authors: Høj L, Nykjær K M, Grønbæk H, ...
#1084 Pancreatic Neuroendocrine Tumors in Denmark and Introduction of Cancer Package Pathways
Introduction: New referral procedures were introduced into the Danish healthcare system on Jan 1, 2009 in malignant diseases. Cancer-package pathways purposed to streamline diagnostics and treatment specifically to reduce the waiting time from diagnosis to initiation of specialized treatment.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: BA Claus Uhrenholt Christensen
Authors: Christensen C U, Grønbæk H, ...